Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
- Statement of Comprehensive Income
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Net Profit Margin since 2005
- Current Ratio since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
The financial ratios reflect significant volatility and sustained negative performance over the examined periods. Key profitability and efficiency indicators highlight persistent challenges.
- Operating Profit Margin
- Operating profit margin has consistently shown deep negative values, indicating continuous operating losses. The margin deteriorated sharply from approximately -252% in early 2019 to a notable low near -6344% by late 2023. This extreme negative margin demonstrates worsening operational efficiency, with a particularly steep decline observed in the last periods of 2022 and into 2023.
- Net Profit Margin
- The net profit margin follows a similar downward trend as operating margin, remaining negative throughout. Starting around -304% in early 2019, the ratio plummeted dramatically past -6700% by the third quarter of 2023. Such a deep and increasing net loss margin suggests escalating costs or diminishing revenues disproportionately impacting the bottom line.
- Return on Equity (ROE)
- ROE data, although sporadic, reveals extremely negative returns for shareholders, with a severe downturn noticed by the end of 2021 reaching nearly -945%. Earlier values fluctuate but remain below zero, emphasizing a failure to generate equity returns across the periods with available data.
- Return on Assets (ROA)
- Return on assets also demonstrates a continuous negative trend, reflecting poor asset utilization in generating profits. Initial values around -53% further declined to approximately -71% by the later quarters in 2023. While the declines are less extreme compared to margins, the persistence of negative figures indicates ongoing inefficiency in asset employment.
Overall, the sustained negative returns and margins signify that the company has faced consistent financial difficulties and has not achieved profitability or asset efficiency in the analyzed timeframe. The worsening trends toward the recent periods highlight increasing financial strain and declining operational control, warranting careful financial restructuring or strategic review.
Return on Sales
Return on Investment
Operating Profit Margin
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Operating income (loss) | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Operating profit margin = 100
× (Operating income (loss)Q3 2023
+ Operating income (loss)Q2 2023
+ Operating income (loss)Q1 2023
+ Operating income (loss)Q4 2022)
÷ (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data over the periods examined reveal consistent challenges in operating performance, with notable volatility in revenue figures and persistent operating losses that significantly affect profitability ratios.
- Operating Income (Loss)
- Operating income or loss figures exhibit a largely negative trend throughout the periods, indicating sustained operating losses. The values fluctuate considerably, with losses generally deepening over time, especially from 2020 onwards. An exceptional positive value appears in Q3 2020, which stands out as an anomaly amidst predominantly negative results. From late 2021 through 2023, the losses are markedly severe, often exceeding one hundred thousand US dollars in the negative, indicating escalating operating difficulties.
- Revenues
- Revenues demonstrate significant inconsistency and volatility across the quarterly periods. Initial quarters show low single-digit thousands, occasionally dropping below four thousand. A substantial spike occurs in several isolated quarters, notably in Q3 and Q4 2020, as well as Q4 2021, where revenues rise sharply into the tens of thousands, suggesting episodes of heightened sales or income. However, these spikes are irregular and followed by periods of reduced revenue, indicating instability in the company’s revenue-generating activities.
- Operating Profit Margin
- The operating profit margin percentages consistently reflect highly negative margins, well below zero throughout all observed quarters. Margins deteriorate significantly over time, with extreme negative percentages reaching multiples of thousands in the most recent quarters, particularly in 2023. This indicates that operating losses are not only persistent but also progressively worsening relative to revenue generation. The margin figures correlate directly with the pattern of operating income losses, underscoring profitability challenges.
Overall, the financial trends point to a company facing severe operational challenges characterized by continuously negative operating income, erratic revenue performance, and greatly unfavorable operating profit margins. The few instances of revenue surges and the isolated positive operating income quarter did not translate into sustained profitability improvements. The data suggest a need for strategic operational and financial restructuring to address the ongoing loss-making trajectory.
Net Profit Margin
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Net loss | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Net profit margin = 100
× (Net lossQ3 2023
+ Net lossQ2 2023
+ Net lossQ1 2023
+ Net lossQ4 2022)
÷ (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data presents a comprehensive view of the company's quarterly performance over several years, focusing primarily on net loss, revenues, and net profit margin.
- Net Loss
- The net loss demonstrates significant variability with an overall increasing trend in magnitude, indicating growing financial challenges. Early periods reflect net losses around the range of -29,000 to -32,000 thousand US dollars. However, sharp fluctuations occur in subsequent quarters, notably an anomalous reduction in net loss to -3,175 thousand in September 2020, followed by a substantial increase to nearly -44,000 thousand by the end of 2020.
- From 2021 onwards, net losses escalate further, peaking in late 2022 with losses exceeding -142,000 thousand US dollars, showing the most substantial quarterly deficit within the dataset. Although slight improvements are observed in early 2023, net losses remain elevated, consistently exceeding -120,000 thousand.
- Revenues
- Revenues exhibit pronounced volatility with no clear upward or downward trend, reflecting inconsistent quarterly earnings. Initial quarters show modest revenues ranging mostly between 3,500 and 8,500 thousand US dollars.
- A significant spike in revenue to over 41,000 thousand occurs in September 2020, followed by substantial rebound to around 55,600 thousand in December 2021 and a peak at nearly 89,968 thousand in mid-2022. These peaks suggest occasional episodic gains but are not sustained.
- After the mid-2022 peak, revenues sharply decline to below 5,000 thousand and remain low through 2023, reaching some of the lowest values in the dataset by the third and fourth quarters of 2023.
- Net Profit Margin
- The net profit margin is consistently deeply negative, illustrating persistent unprofitability. Margins start between approximately -300% and -450%, signaling losses many times larger than revenues.
- Extreme variability is evident, with metrics plunging to beyond -1,000% in late 2021 and an alarming deterioration during 2023, where the margin reaches unprecedented lows exceeding -5,400% and -6,700% by the third and fourth quarters, respectively.
- This severe margin contraction aligns with the increasing net losses and declining revenues, confirming a worsening operating efficiency and financial health especially in recent quarters.
In summary, the data highlights a company facing escalating net losses and erratic revenue generation, culminating in severely negative profitability ratios. While isolated periods show temporary rises in revenues, these do not translate into improved profitability or sustainable financial stability. The financial profile indicates pressing challenges in managing costs and generating consistent income.
Return on Equity (ROE)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Net loss | |||||||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
ROE = 100
× (Net lossQ3 2023
+ Net lossQ2 2023
+ Net lossQ1 2023
+ Net lossQ4 2022)
÷ Stockholders’ equity (deficit)
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Loss
- The company consistently reported net losses throughout the observed periods, with significant fluctuations in magnitude. Initially, net loss values ranged around -29,000 to -40,000 thousand US dollars from early 2019 to mid-2020. A notable reduction occurred in the third quarter of 2020, registering a markedly lower loss of approximately -3,175 thousand US dollars. However, this improvement was short-lived, as losses escalated sharply again by the end of 2020, reaching values exceeding -43,000 thousand US dollars. The trend towards increasing losses continued into the following years, with occasional volatility. The highest losses were observed in the latter half of 2022, peaking at over -142,000 thousand US dollars in the third quarter of 2022. In 2023, net losses remained persistently high, with figures consistently exceeding -120,000 thousand US dollars, indicating ongoing financial challenges.
- Stockholders’ Equity (Deficit)
- The stockholders’ equity position exhibited significant volatility and a predominantly negative trend. Early in the timeline, equity fluctuated near zero with minor positive and negative balances, transitioning into substantial negative territory by mid-2019 and early 2020. A remarkable and anomalous positive surge was observed in the third quarter of 2020, where equity sharply increased to over 149,000 thousand US dollars, followed by a sustained elevated positive range through late 2021, peaking at approximately 249,000 thousand US dollars in the third quarter of 2021. Starting from 2022, equity began to decline again, falling back into negative territory by late 2022. The downward trend deepened throughout 2023, culminating in a significant deficit of over -438,000 thousand US dollars by the third quarter, suggesting worsening financial stability and potential erosion of shareholder value.
- Return on Equity (ROE)
- The return on equity metrics available indicate severe negative returns, reflecting the substantial net losses in comparison to equity. The ROE figures, although incomplete for some periods, highlight extremely negative percentages ranging from approximately -76% to nearly -945%, signifying that the company is not generating positive returns for equity holders and is instead experiencing considerable value erosion. These negative returns peak notably in late 2020 and early 2021 periods, consistent with the periods of large net losses and fluctuating equity positions.
- Summary of Trends and Insights
- Overall, the financial data reveals a company experiencing persistent and increasing net losses over multiple years, with only brief or isolated improvements. Stockholders’ equity shows periods of unusual large positive spikes, possibly indicating capital injections or asset revaluations, but eventually trends back into substantial negative equity, signaling ongoing financial distress. The negative ROE underscores an ineffective utilization of equity capital and sustained unprofitability. These patterns suggest significant challenges in achieving financial turnaround, highlighting the need for strategic financial restructuring or operational improvements to restore profitability and equity stability.
Return on Assets (ROA)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Net loss | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
ROA = 100
× (Net lossQ3 2023
+ Net lossQ2 2023
+ Net lossQ1 2023
+ Net lossQ4 2022)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Loss Trend
- The net loss exhibits significant fluctuations over the analyzed periods. Starting from a loss of approximately $29.4 million in the first quarter of 2019, the losses increased moderately through 2019 and early 2020, with notable peaks and troughs. A substantial reduction in loss is observed in Q3 2020, dropping to around $3.2 million, followed by a sharp rise again in Q4 2020. In the subsequent quarters, losses reached considerable highs, with a peak exceeding $142 million in Q3 2022. In the most recent periods, net losses have somewhat stabilized but remain elevated above $120 million, indicating persistently high expenses or reduced revenues.
- Total Assets Trend
- Total assets demonstrate an overall increasing trend with some volatility. The assets started at approximately $199 million in the first quarter of 2019 and showed gradual increases through 2019 and 2020, reaching over $800 million by late 2021. After peaking above $1 billion in early 2022, total assets declined steadily throughout 2022 and 2023, settling near $740 million by Q3 2023. This decline suggests asset liquidation, depreciation, or other factors impacting the asset base in the most recent periods.
- Return on Assets (ROA) Trend
- ROA remains consistently negative throughout the entire timeframe, reflecting the company's unprofitability relative to its asset base. The magnitude of negative ROA fluctuates, starting with values between -40% to -60% in 2019 and early 2020. There is a period during late 2020 and 2021 where ROA improves slightly to approximately -24% to -27%, indicating a marginally better asset utilization or reduced losses relative to assets. However, from late 2022 onwards, ROA deteriorates markedly, reaching values around -70% by Q3 2023, which corresponds to high net losses combined with decreasing total assets, signaling heightened inefficiency in asset use to generate earnings.
- Summary of Financial Position and Performance
- The data reveals a challenging financial environment with large and volatile net losses across all periods. Despite increasing total assets up to early 2022, the company's profitability did not improve, as indicated by persistently negative and worsening ROA. The subsequent decline in total assets along with rising net losses and deteriorating ROA in 2022 and 2023 suggests possible operational difficulties, asset impairments, or strategic shifts. Continued high net losses and downward asset trends may impact future financial stability and require strategic management action to improve operational efficiency and asset utilization.